'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - 55 mins ago
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.
Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:00PM CDT
Alnylam (ALNY) expanded its pipeline with ALN-AGT a subcutaneously administrated RNAi therapeutic that targets AGT.
Gilead to license Sovaldi
at Investor's Business Daily - Mon Sep 15, 5:53PM CDT
The big-cap biotech is licensing its megasuccessful hepatitis C drug Sovaldi to Indian generic-drug makers such as Ranbaxy Labs and Cipla, in addition to U.S.-based Mylan (MYL). One course of the Gilead Sciences (GILD) treatment is currently $84,000...
Final Glance: Biotechnology companies
AP - Mon Sep 15, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.
Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:35PM CDT
Novartis (NVS) presented encouraging data on Lucentis and Jetrea at the EURETINA congress in London.
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 2.58% Sell Off
Comtex SmarTrend(R) - Mon Sep 15, 3:39PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $99.33 to a high of $102.10. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $102.89 on volume of 18.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 2.58% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $99.33 to a high of $102.10. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $102.89 on volume of 18.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Alere and Avanir are big market movers
AP - Mon Sep 15, 3:33PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Eli Lilly's Cyramza Scores in Colorectal Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:30PM CDT
Eli Lilly and Company (LLY) announced that Cyramza met the primary endpoint in a phase III study (RAISE) conducted in patients suffering from metastatic colorectal cancer.
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
Midday Glance: Biotechnology companies
AP - Mon Sep 15, 12:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
3 Reasons McKesson Corporation's Stock Could Rise
Keith Speights, The Motley Fool - Motley Fool - Mon Sep 15, 12:00PM CDT
Biotechs aren't the only hot healthcare stocks. Just look at pharmaceutical distributor and healthcare technology giant McKesson Corporation . It's up around 20% so far this year and has more than doubled over the last couple of years. Can these...
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More
at The Street - Mon Sep 15, 11:47AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and he first tackles the upcoming Alibaba IPO.
Video: Gilead OKs Generic Sovaldi To Expand Access
at Investor's Business Daily - Mon Sep 15, 10:35AM CDT
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) said Monday that it's licensing its megablockbuster hepatitis C drug Sovaldi to seven Indian generic-drug companies to improve access in 91 developing countries. Gilead's stock fell about 2% on...
Why Is Gilead Sciences, Inc. Stock Offering This Drug for Cheap?
Todd Campbell, The Motley Fool - Motley Fool - Mon Sep 15, 10:25AM CDT
Gilead Sciences' Sovaldi has been a game changing therapy for thousands of patients in America and Europe, but patients living in poverty stricken countries in Africa and Asia have been shut out from the drug, which costs $84,000 for 12 weeks of...
Early Glance: Biotechnology companies
AP - Mon Sep 15, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.: